Previously we have explored the effect of such inhibition in the context of another ocular fibrotic process (in proliferative vitreoretinopathy or PVR), using single chain variable fragment antibodies targeted to the N-terminal 30 kDa region of fibronectin (Fn52) or its re-engineered form (Fn52 RGDS)11. This evidence concerns the gene FN1 and CAPN5-related vitreoretinopathy.